Pharmaceutical and biotechnology firms are increasingly offloading preclinical studies to specialized providers to manage costs and accelerate research timelines. This shift is fueled by a robust pipeline of targeted therapies, immunotherapies, and gene-editing treatments, which require sophisticated animal models—such as patient-derived xenografts and humanized mice—to validate efficacy before reaching clinical trials.

North America currently leads the global landscape, accounting for 45% of the market share, supported by a mature regulatory environment and heavy investment from organizations like the National Institutes of Health. Meanwhile, the Asia-Pacific region is emerging as a critical growth engine, offering cost-competitive services and a vast, genetically diverse patient population for translational research. Consolidation remains a defining trend, evidenced by recent strategic moves such as Taconic Biosciences’ acquisition of TransCure BioServices to bolster its humanized model capabilities. As drug developers continue to prioritize speed and specialized expertise, major players including Charles River Laboratories, WuXi AppTec, and Labcorp are scaling their infrastructure to meet the demand for high-quality, regulatory-grade preclinical data.